Patrick J. Ward
Expertise in
49
conditions

Dr. Patrick J. Ward

Hematology Oncology | Oncology
4350 Malsbary Road, 
Blue Ash, OH 
On Staff At
Accepting New Patients
Expertise in
49
conditions
4350 Malsbary Road, 
Blue Ash, OH 

Overview

Patrick Ward is a Hematologist Oncology specialist and an Oncologist in Blue Ash, Ohio. Dr. Ward is highly rated in 49 conditions, according to our data. His top areas of expertise are Lung Cancer, Breast Cancer, Colorectal Cancer, Pleuropulmonary Blastoma, and Tissue Biopsy. Dr. Ward is currently accepting new patients.

His clinical research consists of co-authoring 40 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Ohio State University College Of Medicine, 1997

Residency

Ohio State Wexner Medical Center, Internal Medicine, 2000

Specialties

Hematology Oncology
Oncology

Licenses

Internal Medicine in OH

Board Certifications

American Board Of Internal Medicine

Fellowships

Ohio State Medical Center, Hematology & Oncology, 2003

Hospital Affiliations

Mercy Health - Anderson Hospital
Mercy Health - West Hospital
The Jewish Hospital - Mercy Health
Mercy Health - Clermont Hospital
Mercy Health - Fairfield Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Oncology Hematology Care, Inc
4350 Malsbary Road, Blue Ash, OH 45242

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Biological, Other
Study Drugs: Galinpepimut-S, Pembrolizumab
Study Phase: Phase 1/Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Enrollment Status: Completed
Publish Date: July 19, 2021
Intervention Type: Biological, Drug
Study Drugs: FR? vaccine, Cyclophosphamide
Study Phase: Phase 2
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: March 12, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

40 Total Publications

A phase II trial to evaluate the safety and immunogenicity of two doses of a folate receptor alpha vaccine in patients with triple negative breast cancer.
A phase II trial to evaluate the safety and immunogenicity of two doses of a folate receptor alpha vaccine in patients with triple negative breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 06, 2025
Similar Doctors
David M. Waterhouse
Expertise in
57
conditions
Dr. David M. Waterhouse
Hematology Oncology | Oncology
Expertise in
57
conditions
Dr. David M. Waterhouse
Hematology Oncology | Oncology

Oncology Hematology Care, Inc

3301 Mercy Health Boulevard, Suite 100, 
Cincinnati, OH 
 (12.1 miles away)
888-649-4800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Waterhouse is a Hematologist Oncology specialist and an Oncologist in Cincinnati, Ohio. Dr. Waterhouse is highly rated in 57 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Colorectal Cancer. Dr. Waterhouse is currently accepting new patients.

Evan Z. Lang
Expertise in
119
conditions
Dr. Evan Z. Lang
Hematology Oncology | Oncology
Expertise in
119
conditions
Dr. Evan Z. Lang
Hematology Oncology | Oncology

Oncology Hematology Care, Inc

3050 Mack Road, Suite 300, 
Fairfield, OH 
 (8.5 miles away)
888-649-4800
Languages Spoken:
English
See accepted insurances

Evan Lang is a Hematologist Oncology specialist and an Oncologist in Fairfield, Ohio. Dr. Lang is highly rated in 119 conditions, according to our data. His top areas of expertise are Plummer-Vinson Syndrome, Pleuropulmonary Blastoma, Lung Cancer, Familial Colorectal Cancer, and Bone Marrow Aspiration.

Expertise in
37
conditions
Dr. Edward R. Broun
Hematology Oncology | Oncology
Expertise in
37
conditions
Dr. Edward R. Broun
Hematology Oncology | Oncology
4777 E Galbraith Rd, Ste 320, 
Cincinnati, OH 
 (2.4 miles away)
513-751-2273
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Edward Broun is a Hematologist Oncology specialist and an Oncologist in Cincinnati, Ohio. Dr. Broun is highly rated in 37 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Small Lymphocytic Lymphoma (SLL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Broun is currently accepting new patients.

Frequently Asked Questions about Dr. Patrick J. Ward

How do I make an appointment with Dr. Patrick J. Ward?

You can book an appointment with Dr. Patrick J. Ward by calling their office at 888-649-4800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Patrick J. Ward a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Patrick J. Ward is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Patrick J. Ward specialize in?

While Dr. Patrick J. Ward is a Hematology Oncology, they have specific expertise in Lung Cancer, Breast Cancer, and Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Patrick J. Ward participate in research or clinical trials?

Yes. Dr. Patrick J. Ward has published 40 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Patrick J. Ward's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Patrick J. Ward accept my insurance?

Dr. Patrick J. Ward accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 888-649-4800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ward's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 39 Advanced Conditions
    View All 140 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile